We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
The evolving understanding of risk with calcitonin gene‐related peptide monoclonal antibodies based on real‐world data: A focus on hypertension and Raynaud phenomenon.
- Authors
Breen, Ilana D.; Mangold, Aaron R.; VanderPluym, Juliana H.
- Abstract
In the article, the authors present their retrospective cohort study on the potential risks of calcitonin gene-related peptide monoclonal antibodies (CGRP mAbs) as a preventive treatment of migraine, particularly on hypertension and Raynaud phenomenon (RP). Also cited are some CGRP mAbs drugs like erenumab, galcanezumab, and eptinezumab, and the incidence of microvascular complications as outcome measure of CGRP mAbs.
- Subjects
HYPERTENSION risk factors; THERAPEUTIC use of monoclonal antibodies; RAYNAUD'S disease; MIGRAINE; NEUROPEPTIDES; MONOCLONAL antibodies; CALCITONIN; PREVENTIVE health services; UNITED States. Food &; Drug Administration; MEDICAL appointments; MEDICAL research; CHEMICAL inhibitors; DISEASE risk factors
- Publication
Headache: The Journal of Head & Face Pain, 2021, Vol 61, Issue 8, p1274
- ISSN
0017-8748
- Publication type
Article
- DOI
10.1111/head.14198